The Experts below are selected from a list of 1224 Experts worldwide ranked by ideXlab platform
Mahmoud Elkaissi - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
BMC Pulmonary Medicine, 2021Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:Pulmonary radiological findings of the novel coronavirus disease 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill. However, Lung Cavitation has not been commonly described in these patients. The objective of this study was to assess the incidence of pulmonary Cavitation in patients with COVID-19 and describe its characteristics and evolution. We conducted a retrospective review of all patients admitted to our institution with COVID-19 and reviewed electronic medical records and imaging to identify patients who developed pulmonary Cavitation. Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of patients who developed COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died, and six discharged home. Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
medRxiv, 2020Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:ABSTRACT Background Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary disease have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, Lung Cavitation has not been described in these patients. Objectives To assess the incidence of pulmonary Cavitation and describe its characteristics and evolution. Methods A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary Cavitation. Results Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of those with COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
Zaid Zoumot - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
BMC Pulmonary Medicine, 2021Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:Pulmonary radiological findings of the novel coronavirus disease 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill. However, Lung Cavitation has not been commonly described in these patients. The objective of this study was to assess the incidence of pulmonary Cavitation in patients with COVID-19 and describe its characteristics and evolution. We conducted a retrospective review of all patients admitted to our institution with COVID-19 and reviewed electronic medical records and imaging to identify patients who developed pulmonary Cavitation. Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of patients who developed COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died, and six discharged home. Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
medRxiv, 2020Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:ABSTRACT Background Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary disease have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, Lung Cavitation has not been described in these patients. Objectives To assess the incidence of pulmonary Cavitation and describe its characteristics and evolution. Methods A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary Cavitation. Results Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of those with COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
F Gudiol - One of the best experts on this subject based on the ideXlab platform.
-
Lung Cavitation associated with pneumocystis carinii infection in the acquired immunodeficiency syndrome a report of six cases and review of the literature
European Respiratory Journal, 1994Co-Authors: C Ferre, F Baguena, D Podzamczer, C Sanchez, P F Viladrich, Javier Garau, F GudiolAbstract:Lung Cavitation in patients with the acquired immune deficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) has mainly been reported as single case studies. Among 160 episodes of PCP seen in a 1,000 bed teaching hospital and a 600 bed teaching hospital from 1985-1992, we found six cases presenting with Lung Cavitation and documented Pneumocystis carinii infection. In the cases we report, as well as in the cases reviewed, cavities appear either alone or within an area of pulmonary consolidation, a mass or a nodule. They may present with haemoptysis, show unusual locations, and, most importantly, may frequently be misdiagnosed by bronchoalveolar lavage.
Irfan Shafiq - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
BMC Pulmonary Medicine, 2021Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:Pulmonary radiological findings of the novel coronavirus disease 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill. However, Lung Cavitation has not been commonly described in these patients. The objective of this study was to assess the incidence of pulmonary Cavitation in patients with COVID-19 and describe its characteristics and evolution. We conducted a retrospective review of all patients admitted to our institution with COVID-19 and reviewed electronic medical records and imaging to identify patients who developed pulmonary Cavitation. Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of patients who developed COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died, and six discharged home. Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
medRxiv, 2020Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:ABSTRACT Background Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary disease have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, Lung Cavitation has not been described in these patients. Objectives To assess the incidence of pulmonary Cavitation and describe its characteristics and evolution. Methods A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary Cavitation. Results Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of those with COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
Ali Wahla - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
BMC Pulmonary Medicine, 2021Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:Pulmonary radiological findings of the novel coronavirus disease 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill. However, Lung Cavitation has not been commonly described in these patients. The objective of this study was to assess the incidence of pulmonary Cavitation in patients with COVID-19 and describe its characteristics and evolution. We conducted a retrospective review of all patients admitted to our institution with COVID-19 and reviewed electronic medical records and imaging to identify patients who developed pulmonary Cavitation. Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of patients who developed COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died, and six discharged home. Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
-
pulmonary Cavitation an under recognized late complication of severe covid 19 Lung disease
medRxiv, 2020Co-Authors: Zaid Zoumot, Mariafernanda Bonilla, Ali Wahla, Irfan Shafiq, Mateen Uzbeck, Rania Ellababidi, Fadi Hamed, Mohamed Abuzakouk, Mahmoud ElkaissiAbstract:ABSTRACT Background Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary disease have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, Lung Cavitation has not been described in these patients. Objectives To assess the incidence of pulmonary Cavitation and describe its characteristics and evolution. Methods A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary Cavitation. Results Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary Cavitation, comprising 3.3% (n = 12/359) of those with COVID-19 pneumonia, and 11% (n = 12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the Cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion Cavitary Lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.
